Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Breast Neoplasms 9 Pain, Postoperative 7 Lung Neoplasms 4 Depression 4 Brain Neoplasms 4 Anxiety Disorders 4 Prostatic Neoplasms 3 Pain 3 Ovarian Neoplasms 3 Neoplasms 3 Colonic Neoplasms 3 Agnosia 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Fallopian Tube Neoplasms 2 Delirium 2 Colorectal Neoplasms 2 Warts 1 Uterine Cervical Neoplasms 1 Trauma, Nervous System 1 Thrombosis 1 Synovial Cyst 1 Stroke 1 Spondylosis 1 Spondylolisthesis 1 Spinal Stenosis 1 Sleep Initiation and Maintenance Disorders 1 Sigmoid Neoplasms 1 Sepsis 1

Interventions

pembrolizumab 137 Nivolumab 116 Ipilimumab 68 Cyclophosphamide 33 Specimen Handling 31 Magnetic Resonance Spectroscopy 28 trametinib 23 binimetinib 22 fludarabine 21 Interleukin-2 20 dabrafenib 19 relatlimab 17 encorafenib 17 Biopsy 17 CTLA-4 Antigen 16 cemiplimab 15 atezolizumab 15 aldesleukin 15 Radiosurgery 15 fludarabine phosphate 14 Opdualag 14 Radiotherapy 11 lenvatinib 10 Blood Specimen Collection 10 lifileucel 9 Paclitaxel 8 Cisplatin 8 Bevacizumab 8 spartalizumab 7 cobimetinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × Saline Solution × 1 year × Clear all

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡